Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell ...

    Research Article last updated 10/02/2017 - 10:03am.

  2. Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times

    ... measures captured by patient-reported outcomes (PROs). Myelodysplastic and myelodysplastic/myeloproliferative (MDS/MPN) neoplasm overlap syndromes are notable for significant morbidity and mortality, including a wide ...

    Research Article last updated 09/13/2017 - 8:29am.

  3. Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes

    ... treatment-associated adverse events among patients with myelodysplastic syndromes (MDS) treated with lenalidomide ; such modifications are ...

    Research Article last updated 11/08/2017 - 9:12am.

  4. Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes

    ... review discusses the need for computational modeling in myelodysplastic syndromes (MDS) and early test results. RECENT FINDINGS: As our ...

    Research Article last updated 09/18/2017 - 9:46am.

  5. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

    ... BACKGROUND: Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept ...

    Research Article last updated 09/18/2017 - 1:38pm.

  6. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.

    ... Myelodysplastic syndromes /myeloproliferative neoplasms (MDS/MPN) comprise a spectrum of ...

    Research Article last updated 09/11/2017 - 8:45am.

  7. Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?

    ... Bone Marrow Diseases:  myelodysplastic syndromes (MDS) ...

    Research Article last updated 10/23/2017 - 11:14am.

  8. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R

    ... (NGS) in 179 patients (median age 73 years) with primary myelodysplastic syndromes (MDS); risk distribution according to the revised ...

    Research Article last updated 09/18/2017 - 11:05am.

  9. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis ...

    Research Article last updated 09/13/2017 - 8:58am.

  10. The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression

    ... Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem and progenitor ...

    Research Article last updated 09/13/2017 - 8:25am.